Abstracts tagged "pulmonary"

Abstract Number: 0505 • ACR Convergence 2021
Risk of Venous and Arterial Thromboembolism in Patients with Giant Cell Arteritis And/or Polymyalgia Rheumatica: A Veterans Health Administration Population-Based Study in the United States
Despina Michailidou¹, Tianyu Zhang², Pavlos Stamatis³ and Bernard Ng⁴, ¹Division of Rheumatology, University of Washington, Seattle, WA, ²Department of Biostatistics, University of Washington, Seattle, WA, ³Lund University, Lund, Sweden, ⁴Rheumatology Section, VA Puget Sound HCS, University of Washington, Seattle, WA
Background/Purpose: Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are two chronic systemic inflammatory diseases that primarily affect elderly women. Both diseases can be complicated…
Abstract Number: 1002 • ACR Convergence 2021
Nerve and Airway-associated Tissue Resident Pulmonary Macrophages Limit Infiltration and Alter Phenotype of Infiltrating Monocytes and Fibrocytes to Reduce Pulmonary Fibrosis
Robert Freilich¹ and Kamal Khanna², ¹New York University Department of Rheumatology, New York, NY, ²New York University Department of Rheumatology & Microbiology, New York, NY
Background/Purpose: Macrophages and monocytes are increasingly implicated in the pathogenesis of autoimmune induced pulmonary fibrosis. In addition to the well-recognized classes of tissue resident macrophages…
Abstract Number: 1100 • ACR Convergence 2021
Pulmonary Arterial Hypertension in Adult-Onset Still’s Disease: A Case Series of 13 Patients
Stéphane Mitrovic¹, athénaïs Boucly², Estibaliz Lazaro³, Nicolas SCHLEINITZ⁴, Coralie Bloch-Queyrat⁵, Christine Christides⁶, Jacques Pouchot⁷, marc humbert², David Montani², laurent savale², Xavier Jaïs², Olivier Sitbon² and Bruno Fautrel⁸, ¹Pitié Salpêtrière Hospital - Institut Mutaliste Montsouris, Paris, France, ²Pneumology Department, Bicêtre Hospital, Assistance Publique – Hôpitaux de Paris, Kremlin-Bicêtre, France, ³Internal Medicine Department, CHU Bordeaux, Pessac, France, ⁴Internal Medicine Department, Hôpital Timone, APHM, Marseille, France, ⁵Internal Medicine Department, Avicennes Hospital, APHP, Bobigny, France, ⁶Internal Medicine Department, CH Avignon, Avignon, France, ⁷AP-HP, RUEIL-MALMAISON, France, ⁸Pitié Salpêtrière Hospital, APHP, Sorbonne Université, Paris, France
Background/Purpose: Pulmonary Arterial Hypertension (PAH) is a rare but potentially fatal complication of Adult-Onset Still's Disease (AOSD). To date, only isolated observations have been published.…
Abstract Number: 1370 • ACR Convergence 2021
Complement Factor D and Factor H Represent Disease and Severity Biomarkers for Systemic Sclerosis Associated Pulmonary Arterial Hypertension (SSc-PAH)
Roberta G Marangoni¹, Changyong Feng¹, Ashley Frazer-Abel², Stephen Tomlinson³, Amy Wielgosz¹, Katie Lutz⁴, Michael Pauciulo⁴, William Nichols⁴, V. Michael Holers⁵, Christopher Ritchlin⁶, R James White III¹ and Benjamin Korman¹, ¹University of Rochester, Rochester, NY, ²University of Colorado Denver, Colorado, CO, ³Medical University of South Carolina, Charleston, SC, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵University of Colorado, Denver, CO, ⁶Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Pulmonary arterial hypertension (PAH) is a severe vascular complication of systemic sclerosis (SSc) and a major cause of mortality. Despite significant advances in the…
Abstract Number: 1379 • ACR Convergence 2021
Serum Levels of the Soluble Receptor for Advanced Glycation Endproducts Are Prospectively Associated with Pulmonary Arterial Hypertension in Systemic Sclerosis
Isabella Atzeni¹, Yehya Al-Adwi², Berber Doornbos-van der Meer², Anniek Van Roon², Caroline Roozendaal¹, Andries Smit², Alja J. Stel², Harry Van Goor², Tji-Joong Gan¹, Johanna Westra² and Douwe J Mulder², ¹University of Groningen, University Medical Centre Groningen, Groningen, Groningen, Netherlands, ²University of Groningen, University Medical Centre Groningen, Groningen, Netherlands
Background/Purpose: Interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH) are the leading causes of death in Systemic Sclerosis (SSc). Markers for early detection of…
Abstract Number: 1385 • ACR Convergence 2021
Overall Survival in Patients with Systemic Autoimmune Diseases Following Lung or Heart-Lung Transplantation at a Single High-Volume Academic Transplant Center: A Comparative Cohort Study
Jason Melehani¹, Shufeng Li², Joshua Mooney³ and Lorinda Chung², ¹Stanford University, San Jose, CA, ²Stanford University, Palo Alto, CA, ³Stanford University, Stanford, CA
Background/Purpose: Lung manifestations of systemic autoimmune diseases are a frequent cause of early death. For many patients, current treatments cannot arrest the inexorable progression to…
Abstract Number: 1386 • ACR Convergence 2021
Measurement of TIMP-1 in Pulmonary Vessels May Be a Novel Marker of Reflecting mPAP in CTD-PH
Shusaku Nakashima¹, Kaori Ishikawa¹, Kiyo Ueeda¹, Tomohiro Kameda¹, Hiromi Shimada¹, Risa Wakiya¹, Mansour mai¹, Mikiya Kato¹, Taichi Miyagi², Koichi Sugihara¹, Rina Semba¹, Mao Mizusaki¹ and Hiroaki Dobashi³, ¹Kagawa University, Takamatsu, Japan, ²Kagawa University, Kidagun, Japan, ³Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan
Background/Purpose: CTD is a disease with immune abnormalities which could alter normal cytokine profile. CTD-PH has a different pathogenesis from that of iPAH, and immunosuppressive…
Abstract Number: 1662 • ACR Convergence 2021
Unrecognised, Subclinical, Structural or Functional Lung Changes in Rheumatoid Arthritis Is Associated with a Higher Risk of Developing Serious Respiratory Tract Infection
Benjamin Worcester¹, Dorothy Wang², Susan Morton³ and Michelle Leech⁴, ¹Monash Health, Melbourne, Australia, ²Melbourne Health, Clayton, Australia, ³Monash Health, Clayton, Australia, ⁴Monash Medical Centre, Australia, Australia
Background/Purpose: The incidence of lung disease within the rheumatoid arthritis is well described and likely underestimated. Additionally, RA patients are at higher risk for developing…
Abstract Number: L04 • ACR Convergence 2020
Influenza Adverse Events in Patients with Rheumatoid Arthritis in the Tofacitinib Clinical Program
Kevin L Winthrop¹, Arne Yndestad², Dan Henrohn³, Hyejin Jo⁴, Sara Marsal⁵, Maria Galindo⁶, Annette Diehl⁷, Andrea B Shapiro⁸ and Stanley B Cohen⁹, ¹Oregon Health & Science University, Portland, OR, ²Pfizer Inc, Oslo, Norway, ³Pfizer Inc, Sollentuna, Sweden, ⁴Syneos Health, Raleigh, NC, ⁵Vall d’Hebron Hospital, Barcelona, Spain, ⁶Rheumatology Unit, Hospital Universitario 12 de Octubre, Madrid, Spain, ⁷Pfizer Inc, Collegeville, PA, ⁸Pfizer Inc, Peapack, NJ, ⁹Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: Patients (pts) with RA have increased susceptibility to seasonal influenza and its complications.1 The COVID-19 pandemic highlights the need to understand acute respiratory RNA…
Abstract Number: 0925 • ACR Convergence 2020
Early Hydroxychloroquine Use May Reduce Risk for SSc-Associated Pulmonary Hypertension
Alexandra Boucher¹, Yongseok Park², Shannon Zalewski³, Maureen Laffoon², Thomas Medsger⁴, Robert Lafyatis² and Robyn Domsic⁵, ¹University of Pittsburgh, Camp Hill, PA, ²University of Pittsburgh, Pittsburgh, PA, ³Washington University Barnes Jewish Hospital, Saint Louis, MO, ⁴University of Pittsburgh School of Medicine, Verona, PA, ⁵University of Pittsburgh School of Medicine, Pittsburgh, PA
Background/Purpose: Systemic sclerosis (SSc) patients are at high risk for pulmonary hypertension (PH), a leading cause of death in this population. Chloroquine is a pulmonary…
Abstract Number: 1038 • ACR Convergence 2020
STAT1 and JAK2 Are the Most Appropriate Targets of JAK-inhibitor Therapy for Sarcoidosis: An In-silico Meta-nalysis
Marcia Friedman¹, Brian Le², Dongseok Choi² and James Rosenbaum², ¹Oregon Health and Science University, Portland, OR, ²Oregon Health & Science University, Portland, OR
Background/Purpose: Our group was the first to contend that STAT1 mediated genes were expressed in sarcoidosis. Since that time, several other groups have found similar…
Abstract Number: 1039 • ACR Convergence 2020
Tofacitinib as a Steroid-sparing Therapy in Pulmonary Sarcoidosis: Two Prospective Cases and Molecular Analysis
Marcia Friedman¹, Stevens Janelle², Julianna Desmarais³, Daniel Seifer³, Brian Le³, Kimberly Ogle³, Christina Harrington³, Peter Jackson⁴, Dongseok Choi³ and James Rosenbaum³, ¹Oregon Health and Science University, Portland, OR, ²Tuality Healthcare, Hillsboro, OR, ³Oregon Health & Science University, Portland, OR, ⁴Johns Hopkins University, Baltimore, MD
Background/Purpose: Patients with pulmonary sarcoidosis often require prolonged corticosteroids to treat their disease. There are currently no FDA approved steroid-sparing therapies for sarcoidosis. We report…
Abstract Number: 1040 • ACR Convergence 2020
Clinical Characteristics of Sarcoidosis in Asian Population: A 14-year Single Center Retrospective Cohort Study from Thailand
Athiwat Tripipitsiriwat¹, Chulaluk Komoltri¹, Ruchira Ruangchira-Urai¹ and Patompong Ungprasert², ¹Mahidol University, Bangkok, Thailand, ²Cleveland Clinic, Cleveland, OH, Cleveland Heights, OH
Background/Purpose: Data on clinical manifestations of Asians with sarcoidosis are still relatively limited and most of the previously published studies are from East Asia. This…
Abstract Number: 1051 • ACR Convergence 2020
Rituximab for Interstitial Pneumonia with Autoimmune Features at Two Academic Medical Centers
Kristin D'Silva¹, Iazsmin Bauer Ventura², Marcy Bolster³, Flavia Castelino⁴, Amita Sharma¹, Brent Little¹, Ayodeji Adegunsoye², Mary Strek², Sydney Montesi¹ and Hyon Choi⁵, ¹Massachusetts General Hospital, Boston, MA, ²University of Chicago, Chicago, IL, ³Massachusetts General Hospital, Concord, MA, ⁴Massachusetts General Hospital/Harvard Medical School, Boston, MA, ⁵Massachusetts General Hospital, Department of Medicine, Division of Rheumatology, Lexington, MA
Background/Purpose: Many patients with interstitial lung disease (ILD) have autoimmune features without a distinct rheumatic disease and are thus designated as having interstitial pneumonia with…
Abstract Number: 0015 • ACR Convergence 2020
COVID -19 Lung Inflammation – What Have We Learnt so Far ?
Sriya Gokaraju¹, Maria Darda², Vinod Vijayaraghavan Nalini Warrier³, Irina Duta³, Fiona Hayes³, Yasser Ahmed⁴ and Gouri Koduri³, ¹Southend University Hospital NHS Trust, Essex, United Kingdom, ²Southend University Hospital NHS Trust, Essex, United Kingdom, ³Southend University Hospital NHS Trust, Essex, United Kingdom, ⁴Southend University Hospital, Essex, United Kingdom
Background/Purpose: The SARS CoV-2 pandemic has inspired new interest in understanding the fundamental pathology of pneumonia and Acute Respiratory Distress Syndrome (ARDS). SARS CoV-2 in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].